



Date: 24 November 2022

To, **The General Manager, Corporate relationship department, BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 Ref No.: TCPCL/SEC/2022-23/00080

The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra-Kurla, Complex Bandra(E), Mumbai-400 051

Scrip Code: 543321

Scrip Symbol: TATVA

Subject: Intimation of Schedule of Analyst/ Institutional Investor meeting.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby submit schedule of analyst/institutional investors meeting that the Company would be participating:

Date	Particulars	Туре	Mode
25 November 2022	Marcellus Investment	One-on-One	Physical meeting
	Managers		
25 November 2022	Capital Group	One-on-One	Physical meeting

Please note that the above is subject to change, if any.

The above information shall be uploaded on the website of the Company at <u>www.tatvachintan.com</u>.

Kindly take the above disclosure on your records.

Thanking You,

Your Faithfully, For Tatva Chintan Pharma Chem Limited

Ishwar Nayi Company Secretary and Compliance Officer M. No.: A37444

Registered Office and Factory: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. : +91 75748 48533 / 34 Fax : +91 265 263 8533 E-mail : cs@tatvachintan.com Website : www.tatvachintan.com